• Most studies for the treatment of AKs in OTRs focused on photodynamic therapy, which showed the highest clearance rates among all interventions, while ablative laser treatment alone showed poor efficacy.
• Our findings suggest that lesion-specific regimens may not be sufficient to achieve disease control and underline the importance of field-directed treatments in OTRs.
Organ transplant recipients (OTRs) with systemic immunosuppression are at high risk for the development of actinic keratoses (AKs) and cutaneous malignancies. The likelihood of a single AK lesion progressing to invasive squamous cell carcinoma is empirically far higher in OTRs than in the general population, although exact progression rates have not been identified in OTRs. 1 The introduction of mammalian target of rapamycin (mTOR)-based regimens has revealed more favourable results than calcineurin inhibitors regarding the incidence of nonmelanoma skin cancer (NMSC) and early conversion to mTOR inhibitors can help to decrease the excess risk of skin cancer. [2] [3] [4] [5] However, long-term treatment impairs immunosurveillance and clearance of precancerous skin lesions. 6 Furthermore, immunosuppressants such as ciclosporin and azathioprine exhibit a direct carcinogenic potential independent of the host's immunity. 7 Other risk factors, such as male sex, sun exposure, fair skin or advancing age, can further increase the propensity of OTRs to develop NMSC. Thus, meticulous post-transplantation surveillance with early and consequent treatment of AKs and field cancerization is warranted. A variety of local interventions are available to treat AKs with high patient-and lesion-specific clearance rates. However, the majority of randomized controlled trials (RCTs) and numerous published treatment guidelines focus on patients with a normal immune function, which makes it difficult to reach an evidence-based treatment decision for the OTR population. 8 Here, we performed a systematic review to summarize the current evidence for nonsystemic treatments of AKs in OTRs and to provide a framework for clinical decision making.
Materials and methods

Protocol and registration
The protocol for this review was defined a priori and registered online in the PROSPERO international prospective register of systematic reviews on 28 March 2018 with an amendment on 16 April 2018 (http://www.crd.york.ac.uk/ PROSPERO/display_record.php?ID=CRD42018089754). The register ID was PROSPERO 2018 CRD42018089754. This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 9 The authors closely adhered to the recommendations of the Cochrane Handbook for Systematic Reviews.
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Eligibility criteria
Eligibility was restricted to patients with AKs, diagnosed either clinically or confirmed by histopathology, who had any type of systemic immunosuppression after organ transplantation.
To be included, patients must have been treated with a nonsystemic local treatment. Combination and sequential therapies were allowed. Systemic regimens of chemoprevention, such as nicotinamide or oral retinoids, were not considered. As we wanted to include the highest possible standard of evidence, RCTs were the only type of study design considered. The randomization had to refer to study participants (interindividual studies) or entire treatment areas (right vs. left side in intraindividual studies) and not to individual lesions. Language restrictions applied, as only records published in English or German were included.
Search strategy and databases
We 
Selection process
Two authors (M.V.H. and T.S.) independently screened titles and abstracts that were identified in the electronic database searches for eligibility. Trial registers were hand-searched and assessed for eligibility by one author (T.S.). For records that were considered relevant according to title and abstract screening, full-text articles were obtained and checked for inclusion and exclusion criteria. Whenever discrepancies arose, resolution was achieved by discussion with a third independent author (C.B.).
Outcomes
The primary outcomes were participant complete clearance rate determined by the number of patients or randomized treatment areas with completely cleared lesions (absolute values or percentages) lesion clearance defined as the reduction of lesion counts from baseline to assessment (absolute values or percentages) and transplant rejection or evidence for worsening of transplanted organ function, quantified by the number of patients with transplant rejection or worsening of organ function. Secondary outcomes were the number of patients with local skin reactions (LSRs) and the number of patients with treatment-induced hyper-or hypopigmentation as a cosmetic outcome resulting from treatment. Primary and secondary outcomes had to be reported at least 2 months and not more than 6 months after the end of treatment.
Data collection, synthesis and management
Information on study design, baseline characteristics, type of intervention and risk of bias in addition to information on the primary and secondary outcomes were collected for each study and summarized by two authors independently (M.V.H. and T.S.) on an internally piloted data extraction spreadsheet using Microsoft Excel 2010. If the information on outcomes was insufficient, the authors of the respective study were contacted to obtain more detailed data. The baseline characteristics and the outcomes of interest of each study were qualitatively described within the text. Relative risks were calculated for the outcomes 'participant complete clearance' and 'lesion clearance' with RevMan version 5Á3.
Risk of bias assessment
Two authors (M.V.H. and T.S.) independently assessed the risk of bias of the included studies with the Cochrane Risk of Bias Tool. 10 Discrepancies were discussed and resolved using the information provided by the full texts and supplementary material.
Results
Study identification
Our literature search identified 663 references. After removing duplicates, 611 records remained. Following title and abstract screening, 591 studies were not considered relevant as they did not meet the inclusion criteria. Five of these records were not available in English. To identify unpublished data from clinical trials, the principal investigators of nine studies were contacted. Five replied to our requests, but none provided unpublished results. Twenty records underwent full-text review ( Fig. 1 ). Of these 20 records, 12 were excluded because the efficacy outcomes were unclear or none of the outcomes of interest were reported. [11] [12] [13] [14] [15] [16] Study design and randomization process were indefinite in three studies. [17] [18] [19] A further three studies were excluded as the population did not meet the criterion of having a target population of OTRs with systemic immunosuppression. [20] [21] [22] Finally, eight RCTs with a total sample size of 242 patients (range 8-81) met our eligibility criteria and were included in the qualitative synthesis.
Owing to the heterogeneity of comparisons and interventions, a quantitative synthesis with meta-analysis was not possible. Six of the eight included studies had an intraindividual design and investigated some type of photodynamic therapy (PDT) ( Tables S4 and S5 ). 24 Eight were kidney recipients, one patient was a liver transplant recipient and one patient was a heart transplant recipient. Lesion clearance was significantly higher for AFXL-PDT (73%, range 25-94) compared with AFXL alone (31%, range 8-57) (P = 0Á002) after 4 months. Overall, 30% (three of 10) of patients in the AFXL-PDT group vs. 10% (one of 10) in the monotherapy group experienced hypopigmentation. The authors stated that three patients reported LSRs such as erythema, oedema or pain 1 week after treatment. However, it remained unclear in which treatment group those LSRs occurred. Moreover, neither the outcome participant complete clearance nor transplant rejection were specifically reported.
The study was at high risk for reporting bias.
Methyl aminolaevulinate photodynamic therapy vs.
5-fluorouracil 5% cream
Perrett et al. compared MAL-PDT with 5-FU 5% cream. 25 Seven patients were kidney recipients and one patient had a combined kidney and liver transplantation. Evaluation was performed at 1 month, 3 months and 6 months after treatment. Overall, PDT was more effective than 5-FU. After 3 months, 89% of the lesional areas were completely cleared in the MAL-PDT group. The rate remained at 89% at 6 months, whereas only 11% of patients in the 5-FU group achieved a complete clearance of lesional fields at 3 months and 6 months, respectively. The lesion clearance rate was 99% in the MAL-PDT group and 79% in the 5-FU group. No patient experienced a transplant rejection. Hyperpigmentation was reported in 11% of patients in the MAL-PDT group and in 0% of patients in the 5-FU group. The study was at high risk for performance, detection and reporting bias.
Methyl aminolaevulinate photodynamic therapy vs. cryotherapy
Wennberg et al. compared MAL-PDT with lesion-specific interventions (83% cryotherapy) in 81 transplant recipients. 26 Most patients (n = 67) were kidney recipients, 10 were heart recipients and four had liver or lung transplantations. After 3 months, the lesion clearance rate was 77% (95% CI 72-81%) in the MAL-PDT group compared with 74% (95% CI 69-79%) in the control group. Erythema and crusting were reported for 75% of patients (61 of 81) in the MAL-PDT group, whereas only 48% of patients (39 of 81) in the control group reported LSRs. Hypopigmentation was less common in MAL-PDT-treated areas compared with cryotherapy at 27 months (16% vs. 51%). Information on the outcomes participant complete clearance and transplant rejection was not specifically reported. The study was at high risk for performance, detection and attrition bias. Laser-assisted daylight methyl aminolaevulinate photodynamic therapy vs. daylight methyl aminolaevulinate photodynamic therapy vs. conventional methyl aminolaevulinate photodynamic therapy vs. laser alone Togsverd-Bø et al. investigated 16 patients (12 kidney recipients, three lung recipients and one liver recipient). 27 Four areas were randomized to ablative laser-assisted daylight MAL-PDT (AFXL-dl-PDT), daylight MAL-PDT (dl-PDT), conventional MAL-PDT (c-PDT) or ablative laser alone (AFXL). After 3 months, the lesion clearance rate was highest for AFXL-dl-PDT (74%, range 37-100) vs. 50% (range 25-83), 46% (range 0-75) and 5% (range 0-40) for the dl-PDT, c-PDT and AFXL groups, respectively. Erythema and crusting occurred in all areas treated with PDT and were reported as most intense in the AFXL-dl-PDT group. Hypo-and hyperpigmentation were restricted to the AFXL-dl-PDT group occurring at a rate of 12% (two of 16 patients). Data on the outcomes participant complete clearance and transplant rejection were not reviewed. The study was at high risk for performance and reporting bias.
Methyl aminolaevulinate photodynamic therapy vs. imiquimod 5% cream
Togsverd-Bø et al. evaluated 28 kidney, four liver and three lung transplant recipients. 28 Two areas were randomized to MAL-PDT (n = 25) or 5% imiquimod cream (n = 29). After two treatments the participant complete clearance rate was higher for MAL-PDT than for imiquimod (40% vs. 28%, respectively). The lesion clearance was superior for MAL-PDT (78% vs. 61%, respectively). No transplant rejection or changes in pigmentation were observed for either intervention. Intense inflammatory LSRs were significantly more common in the PDT group (median 2Á8) compared with the imiquimod group (median 1Á7). However, these resolved faster in patients treated with PDT (median 10 vs. 18 days, P < 0Á01). The study was at high risk for performance bias.
Imiquimod 5% cream vs. vehicle
Ulrich et al. performed a study in which 43 patients (30 kidney recipients, nine heart recipients and four liver recipients) were randomized to imiquimod 5% (n = 29) or vehicle cream (n = 14). 29 The participant complete clearance rate was 62% (18 of 29) for the active and 0% (none of 14) for the vehicle group. The lesion clearance was 73Á7% in the imiquimod group, whereas new lesions developed in the control arm. LSRs included mild-to-moderate erythema and erosion in the active group. Six of the patients (30%) in the imiquimod group (all kidney transplant recipients) experienced severe erythema. LSRs were not specifically addressed for the control group. No graft rejections or trends for a deterioration of graft function were detected after either intervention. The study was at high risk for reporting bias.
Diclofenac sodium 3% in hyaluronic acid 2Á5% vs. vehicle
Ulrich et al. investigated 32 OTRs (n = 18 kidney/pancreas, n = 8 heart, n = 6 liver) randomized to diclofenac sodium 3% (n = 24) or vehicle (n = 8). 30 Participant complete clearance was achieved in 41% (nine of 22) in the active group vs. 0% (none of six) in the vehicle group. Lesion clearance was also higher in the diclofenac group (53% compared with 17% in the vehicle group at week 16). No transplant rejections or signs of deterioration of the transplant were observed in either group. The most common LSRs included desquamation, erythema and itching, which was more frequently reported in the vehicle group. The authors did not specifically report information on the incidence of pigmentation changes. The study was at high risk for attrition and reporting bias, in addition to other biases.
Discussion
There is surprisingly little evidence relating to the treatment of AK in OTRs available from RCTs. Many studies were of poor quality. MAL-PDT showed the highest rates for participant complete clearance (40-76Á4%), which were lower for imiquimod (27Á5-62Á1%), diclofenac (41%) and 5-FU (11%). Similar results were observed for lesion clearance rates, identifying MAL-PDT as a highly effective approach in OTRs, although cross-trial comparisons should be interpreted with caution. A combination of ablative laser with MAL-PDT was superior to laser or PDT alone in two studies, 24, 27 albeit at the cost of more cases with pigmentation changes. Other LSRs such as erythema and crusting were also reported as most intense in participants treated with a combination of AFXL and daylight MAL-PDT. 27 These results suggest that a combination treatment has high efficacy but should be reserved for difficult-to-treat lesions such as hyperkeratotic AKs or lesions located on the dorsal hands. In addition, the lesion clearance was similar for conventional MAL-PDT (50%) and daylight MAL-PDT (46%) in this study, suggesting that the latter is a valid treatment alternative in OTRs. 27 Treatment with AFXL alone was clearly inferior to MAL-PDT and revealed rather poor lesion clearance rates of 5-31% in two studies. 24, 27 In contrast, observations from RCTs in immunocompetent patients treated with ablative CO 2 laser have reported higher lesion-specific remission rates ranging from 72Á4% to 91Á1%. 31, 32 Thus, ablative laser treatment may not be the first-choice therapy for AKs in OTRs.
Overall, the efficacy rates appeared to be slightly lower than those observed from trials conducted in patients who were nonimmunocompromised. Three studies included in the qualitative synthesis had no active interventions in their control arms and were either placebo-or vehicle-controlled. 24, 29, 30 It is notable that both efficacy outcomes investigated here were commonly reported as 0%. This is in contrast to RCTs involving immunocompetent patients with clearance rates of 30% without any active treatment. These data underline that the natural course of AKs is less favourable in OTRs and that a spontaneous resolution is not likely to occur as proposed for general populations. 1 Thus, transplant recipients should undergo professional complete skin examinations on a regular basis and should be treated if AKs become manifest. The interpretation of safety and tolerability is limited as six of eight studies were estimated to have high risk for selective reporting. Specifically, the frequency and distribution of LSRs among treatment groups were poorly reported. In the largest study, cryosurgery showed considerably lower values for LSR compared with MAL-PDT and had a similar efficacy. 26 These results suggest that cryosurgery may be preferable regarding local skin irritation, particularly considering the easy and costeffective use of this therapy. No transplant rejection or evidence for worsening of the transplanted organ function was observed in the studies that explicitly reported this outcome (n = 4). This end point is of particular interest for agents that modulate the innate immune response as the principal mechanism of action. Concerns about transplant safety have been raised by a case report of a kidney transplant recipient who developed acute tubular necrosis following topical imiquimod treatment. 33 In our analysis, two studies evaluated imiquimod 5% cream applied three times per week. Regarding efficacy, it was inferior to MAL-PDT in a recent head-to-head comparison achieving a participant complete clearance of 27Á5% and a lesion clearance of 61%. 28 Better results were obtained by Ulrich et al. who observed clearance rates of 62Á1% and 73Á7%, respectively. 29 The differences may be due to distinct study designs and treatment durations. However, neither trial detected a transplant rejection or a deterioration of the graft function, which is consistent with some other reports. [34] [35] [36] Nevertheless, imiquimod 5% cream is not approved for OTRs and its use remains off- label in Germany. Although evidence from RCTs for other topical agents was not identified here, they may be applied in the clinical routine with good efficacy and safety regarding the graft function. The limitations of this review include the high heterogeneity of the included studies, small sample sizes and the different immunosuppressive regimens of the included population. We have restricted our search to records available in English or German, resulting in a potential language bias. Conclusions on the long-term efficacy and the preventive effect for invasive squamous cell carcinoma were not possible, because these outcomes were not consistently reported. Better trials with a longer observation period are urgently needed for the OTR population. Although MAL-PDT was the best-studied intervention here, this does not necessarily mean that it is the best treatment currently available. Surgical approaches may be underrepresented as we included evidence only from RCTs. Nevertheless, excisions are routinely used in OTRs and applicable for hyperkeratotic AKs. A histological examination should be performed on lesions whenever invasive skin cancer is suspected. As we included eight RCTs assessing distinct comparisons of interventions, we did not create a funnel plot to conduct a formal assessment of publication bias. None of the studies identified in the trial registries that were not found in the database searches were included in the synthesis, which may indicate a publication bias. However, contacting the principal investigators revealed that the reason for nonpublication was either that most trials were still ongoing or that the data analysis had not been completed.
Overall, most evidence for the treatment of AKs in OTRs from RCTs was found for MAL-PDT, which also showed the highest clearance rates of all interventions. AFXL treatment alone showed poor lesion clearance, implying that lesion-specific regimens may not be sufficient to achieve disease control and field-directed regimens are preferable in OTRs. There was no evidence for therapy-related transplant rejection or worsening of graft function.
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